Clazakizumab for desensitization in highly sensitized patients awaiting transplantation

被引:23
作者
Vo, Ashley A. [1 ]
Huang, Edmund [1 ]
Ammerman, Noriko [1 ]
Toyoda, Mieko [2 ]
Ge, Shili [2 ]
Haas, Mark [3 ]
Zhang, Xiaohai [4 ,5 ]
Peng, Alice [1 ]
Najjar, Reiad [1 ]
Williamson, Summer [1 ]
Myers, Catherine [1 ]
Sethi, Supreet [1 ]
Lim, Kathlyn [1 ]
Choi, Jua [1 ]
Gillespie, Matthew [1 ]
Tang, Jacqueline [1 ]
Jordan, Stanley C. [1 ]
机构
[1] Cedars Sinai Med Ctr, Comprehens Transplant Ctr, Los Angeles, CA 90048 USA
[2] Cedars Sinai Med Ctr, Dept Transplant Immunol & Lab, Los Angeles, CA 90048 USA
[3] Cedars Sinai Med Ctr, Dept Pathol, Los Angeles, CA 90048 USA
[4] Cedars Sinai Med Ctr, Dept HLA, Los Angeles, CA 90048 USA
[5] Cedars Sinai Med Ctr, Immunogenet Lab, Los Angeles, CA 90048 USA
关键词
alloantibody; classification systems; Banff classification; clinical research; practice; desensitization; dialysis; intravenous immunoglobulin; IVIG; kidney transplantation; nephrology; ANTIBODY-MEDIATED REJECTION;
D O I
10.1111/ajt.16926
中图分类号
R61 [外科手术学];
学科分类号
摘要
Alloantibodies are a significant barrier to successful transplantation. While desensitization has emerged, efficacy is limited. Interleukin-6 (IL-6) is an important mediator of inflammation and immune cell activation. Persistent IL-6 production increases the risk for alloantibody production. Here we report our experience with clazakizumab (anti-IL-6) for desensitization of highly HLA-sensitized patients (HS). From March 2018 to September 2020, 20 HS patients were enrolled in an open label pilot study to assess safety and limited efficacy of clazakizumab desensitization. Patients received PLEX, IVIg, and clazakizumab 25 mg monthly X6. If transplanted, graft function, pathology, HLA antibodies and regulatory immune cells were monitored. Transplanted patients received standard immunosuppression and clazakizumab 25 mg monthly posttransplant. Clazakizumab was well tolerated and associated with significant reductions in class I and class II antibodies allowing 18 of 20 patients to receive transplants with no DSA rebound in most. Significant increases in T-reg and B-reg cells were seen posttransplant. Antibody-mediated rejection occurred in three patients. The mean estimated glomerular filtration rate at 12 months was 58 +/- 29 ml/min/1.73 m(2). Clazakizumab was generally safe and associated with significant reductions in HLA alloantibodies and high transplant rates for highly-sensitized patients. However, confirmation of efficacy for desensitization requires assessment in randomized controlled trials.
引用
收藏
页码:1133 / 1144
页数:12
相关论文
共 50 条
  • [21] Kidney transplantation after desensitization in sensitized patients: a Korean National Audit
    Huh, Kyu Ha
    Kim, Beom Seok
    Yang, Jaeseok
    Ahn, Jeongmyung
    Kim, Myung-Gyu
    Park, Jae Berm
    Kim, Jong Man
    Chung, Byung-Ha
    Kim, Joong Kyung
    Kong, Jin Min
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2012, 44 (05) : 1549 - 1557
  • [22] Transplantation of highly sensitized patients via the acceptable mismatch program or desensitization? We need both
    Doxiadis, Ilias I. N.
    Claas, Frans H. J.
    CURRENT OPINION IN ORGAN TRANSPLANTATION, 2009, 14 (04) : 410 - 413
  • [23] Pharmaceutical Costs of Desensitization Therapy in Patients Awaiting Lung Transplantation in France
    Liu, Annae
    Bernard, Melisande
    BIODRUGS, 2014, 28 (01) : 55 - 61
  • [24] Desensitization strategies in the patient awaiting heart transplantation
    Chang, David H.
    Kobashigawa, Jon A.
    CURRENT OPINION IN CARDIOLOGY, 2017, 32 (03) : 301 - 307
  • [25] Progress in Desensitization of the Highly HLA Sensitized Patient
    Jordan, S. C.
    Choi, J.
    Kahwaji, J.
    Vo, A.
    TRANSPLANTATION PROCEEDINGS, 2016, 48 (03) : 802 - 805
  • [26] Kidney Transplant in Highly Sensitized Patients After Desensitization With Plasmapheresis and Low-dose Intravenous Immunoglobulin
    Yuan, Xiao-Peng
    Wang, Chang-Xi
    Gao, Wei
    Fu, Qian
    He, Xiao-Shun
    EXPERIMENTAL AND CLINICAL TRANSPLANTATION, 2010, 8 (02) : 130 - 135
  • [27] Approach to the Sensitized Patient Awaiting Heart Transplantation
    Patel J.K.
    Kobashigawa J.A.
    Current Transplantation Reports, 2014, 1 (4) : 290 - 299
  • [28] New Therapies for Highly Sensitized Patients on the Waiting List
    Vo, Ashley
    Ammerman, Noriko
    Jordan, Stanley C.
    KIDNEY360, 2024, 5 (08): : 1207 - 1225
  • [29] Management of sensitized pediatric patients prior to renal transplantation
    Pirojsakul, Kwanchai
    Desai, Dev
    Lacelle, Chantale
    Seikaly, Mouin G.
    PEDIATRIC NEPHROLOGY, 2016, 31 (10) : 1691 - 1698
  • [30] Kidney transplantation after desensitization in sensitized patients: a Korean National Audit
    Kyu Ha Huh
    Beom Seok Kim
    Jaeseok Yang
    Jeongmyung Ahn
    Myung-Gyu Kim
    Jae Berm Park
    Jong Man Kim
    Byung-Ha Chung
    Joong Kyung Kim
    Jin Min Kong
    International Urology and Nephrology, 2012, 44 : 1549 - 1557